RESUMO
OBJECTIVE： To investigate the occurrence and influencing factors of dry eye in patients with topical use of anti-glaucoma drugs， and to provide reference for the prevention and treatment of dry eye in glaucoma patients. METHODS： Totally 600 patients receiving topical use of anti-glaucoma drugs were selected from our hospital as research objects during Jun. 2015 to Jun. 2018. The ophthalmologic examination and questionnaire survey were carried out. The univariate analysis and multivariate Logistic regression analysis were conducted for influencing factors of dry eye. RESULTS： A total of 600 questionnaires were distributed and 547 questionnaires were recovered， with a recovery rate of 91.17％. Of the 547 patients who withdrew the questionnaire， 36 patients refused to undergo further examination， 19 patients were excluded， and a total of 492 patients were included in the study.Of 492 patients treated with topical anti-glaucoma drugs， there were 262 dry eye patients with incidence of 53.25％. Top 3 symptoms of dry eye were dryness， burning and foreign body sensation， involving 182 cases （69.47％）， 159 cases （60.69％） and 106 cases （40.46％）. The results of univariate analysis showed that there was statistical significance in the difference of gender， age， sleep quality， use of video display terminals， dry environment， medication time， medication types， medication frequency， medication with or without traditional preservatives， pterygium， tarsal gland dysfunction between 2 groups （P＜0.05）. Multivariate Logistic regression analysis showed that gender， medication time， medication type， medication with or without traditional preservatives， tarsal gland dysfunction and video display terminals were risk factors for the occurrence of dry eye in glaucoma patients （OR were 1.613-2.477）. CONCLUSIONS： The incidence of dry eye in patients treated with topical use of anti-glaucoma drug is high. The clinicians should take the prevention and treatment measures according to its risk factors， such as gender， medication time， medication type， medication with or without traditional preservatives， tarsal gland dysfunction and video display terminals， and minimize ocular discomfort in patients with dry eyes so as to improve the therapeutic compliance of glaucoma patients.
RESUMO
PURPOSE: The DBA/2J (D2) mouse is a transgenic mouse with pigmentary glaucoma. In a previous study, we found a reduction of inner retinal thickness in D2 mice. We attempted to discover the effect of eye drops on the retina of D2 mice. METHODS: Ten-month-old D2 mouse eyes were treated with Timoptic XE(R), Cosopt(R), and Xalacom(R) eye drops for a 1-month period. Immunohistochemical staining was performed on the mouse eye sections for analysis. RESULTS: In the control group, GABA and OPN immunoreactivity were markedly decreased and NOS immunoreactivity was increased. In all experimental group, GABA and OPN immunoreactivity were increased, and OPN immunoreactivity was markedly increased especially in the Cosopt(R) group. NOS immunoreactivity was decreased in all experimental groups. There was no difference in glycine immunoreactivity between the control and experimental groups. CONCLUSIONS: Combination anti-glaucoma eye-drops to the D2 mouse changed the retinal neuronal population and these drugs might play an important role in the mechanisms of retinal neuronal death; potential strategies for neuroprotection should therefore be evaluated.